Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Praluent sales to continue as court orders new trial

An appellate court decision will allow hypercholesterolemia drug Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to remain on the market,

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE